Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Siemens Collaborates With Major Private Hospital In Northeast China

This article was originally published in PharmAsia News

Executive Summary

Siemens China has signed a strategic agreement to establish a partnership with Wekang Medicinal Group, the first private Class III hospital in Northeast China. Under the agreement, Siemens will provide Wekang with a full set of radiological and in vitro diagnostic equipment worth about RMB 70 million ($10.2 million), complemented by leasing services; introduce advanced global experience of hospital management procedures and help medical care staff further their studies in overseas hospitals; and assist Wekang to set up a tumor treatment center in the future. The fully equipped Wekang hospital will go into operation in late 2009. Siemens said it is exploring new collaborative models with local corporations by providing leading healthcare products and solutions. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel